Treatment results and prognostic factors for advanced squamous cell carcinoma of the hypopharynx treated with concurrent chemoradiotherapy

详细信息    查看全文

• 作者：Takahide Taguchi (1)
  Goshi Nishimura (1)
  Masahiro Takahashi (1)
  Masanori Komatsu (1)
  Daisuke Sano (1)
  Naoko Sakuma (1)
  Ken-ichiro Yabuki (1)
  Yasuhiro Arai (1)
  Hideaki Takahashi (1)
  Masaharu Hata (2)
  Izumi Koike (2)
  Nobuhiko Oridate (1)
  
• 关键词：Hypopharyngeal cancer ; Treatment results ; Prognostic factors ; Chemoradiotherapy
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：73
• 期：6
• 页码：1147-1154
• 全文大小：
• 参考文献：1. Prades JM, Lallemant B, Garrel R, Reyt E, Righini C, Schmitt T, Remini N, Saban-Roche L, Timoshenko AP, Trombert B, Guerrier B (2010) Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma. Acta Otolaryngol 130:150-55 CrossRef
  2. Hussey DH, Latourette HB, Panje WR (1991) Head and neck cancer: an analysis of the incidence, patterns of treatment, and survival at the University of Iowa. Ann Otol Rhinol Laryngol Suppl 152:2-6
  3. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890-99 CrossRef
  4. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498-06 CrossRef
  5. Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, Blajman CR, Mickiewicz EA, Frenette GP, Plinar LF, Cohen RB, Steinbrenner LM, Freue JM, Gorbunova VA, Tjulandin SA, Raez LE, Adkins DR, Tishler RB, Roessner MR, Haddad RI (2009) Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol 20:921-27 CrossRef
  6. Tsukuda M, Ishitoya J, Matsuda H, Horiuchi C, Taguchi T, Takahashi M, Nishimura G, Kawakami M, Watanabe M, Niho T, Kawano T, Ikeda Y, Sakuma Y, Shiono O, Komatsu M (2010) Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 66:729-36 CrossRef
  7. Taguchi T, Ikeda Y, Mikami Y, Kawai S, Arai Y, Mochimatsu I, Tsukuda M (2003) Combined radiotherapy and chemotherapy with carboplatin and UFT for head and neck squamous cell carcinoma. Anticancer Res 23:713-17
  8. Tsukuda M, Ishitoya J, Mikami Y, Matsuda H, Horiuchi C, Taguchi T, Satake K, Kawano T, Takahashi M, Nishimura G, Kawakami M, Sakuma Y, Watanabe M, Shiono O, Komatsu M, Yamashita Y (2009) Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol 64:945-52 CrossRef
  9. Kodaira T, Fuwa N, Furutani K, Tachibana H, Yamazaki T (2005) Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications. Jpn J Clin Oncol 35:173-76 CrossRef
  10. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-346 CrossRef
  11. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26:3582-589 CrossRef
  12. Suntharalingam M, Haas ML, Van Echo DA, Haddad R, Jacobs MC, Levy S, Gray WC, Ord RA, Conley BA (2001) Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer 91:548-54 CrossRef
  13. Douple EB, Richmond RC, O’Hara JA, Coughlin CT (1985) Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 12(Suppl A):111-24 CrossRef
  14. Colevas AD, Posner MR (1998) Docetaxel in head and neck cancer: a review. Am J Clin Oncol 21:482-86 CrossRef
  15. Fu KK, Phillips TL (1991) Biologic rationale of combined radiotherapy and chemotherapy. Hematol Oncol Clin North Am 5:737-51
  16. Smalley SR, Kimler BF, Evans RG (1991) 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys 20:207-11 CrossRef
  17. Katori H, Tsukuda M, Taguchi T (2007) Concurrent chemoradiotherapy with carboplatin and uracil-f tegafur (UFT) for patients with poor performance status with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Acta Otolaryngol 127:1099-104 CrossRef
  18. Fujii M, Tsukuda M, Satake B, Kubota A, Kida A, Kohno N, Okami K, Inuyama Y (2004) Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol 9:107-12 CrossRef
  19. Lodder WL, Pameijer FA, Rasch CR, van den Brekel MW, Balm AJ (2012) Prognostic significance of radiologically determined neck node volume in head and neck cancer: a systematic review. Oral Oncol 48:298-02 CrossRef
  20. Tsou YA, Hua JH, Lin MH, Tsai MH (2006) Analysis of prognostic factors of chemoradiation therapy for advanced hypopharyngeal cancer—does tumor volume correlate with central necrosis and tumor pathology? ORL J Otorhinolaryngol Relat Spec 68:206-12 CrossRef
  
• 作者单位：Takahide Taguchi (1)
  Goshi Nishimura (1)
  Masahiro Takahashi (1)
  Masanori Komatsu (1)
  Daisuke Sano (1)
  Naoko Sakuma (1)
  Ken-ichiro Yabuki (1)
  Yasuhiro Arai (1)
  Hideaki Takahashi (1)
  Masaharu Hata (2)
  Izumi Koike (2)
  Nobuhiko Oridate (1)
  
  1. Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan
  2. Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
  
• ISSN：1432-0843

文摘

Purpose The purpose of the study is to review our experience with concurrent chemoradiotherapy (CCRT) for patients with advanced resectable squamous cell carcinoma (SCC) of the hypopharynx and to evaluate the factors affecting survival and larynx preservation. Study design Retrospective study. Methods and materials The records of 102 patients with Stage III or IV resectable SCC of the hypopharynx treated with CCRT between January 1998 and August 2010 were reviewed. Of the 102 patients, 62 were treated with high-dose regimens including cisplatin, 5-fluorouracil, methotrexate, leucovorin or docetaxel, cisplatin, and 5-fluorouracil. The remaining 40 were treated with low-dose regimens including carboplatin and uracil-tegafur, weekly docetaxel, or S-1. Radiotherapy was delivered 5?days a week using a single daily fraction of 1.8-.0 Gray (Gy), to a total dose of 64.8-0.2?Gy. Overall survival (OS), disease-specific survival (DSS), and DSS with larynx preservation were estimated using Kaplan–Meier methods. The log-rank test and Cox proportional hazards regression were used to identify significant prognostic factors for OS, DSS, and DSS with larynx preservation. Results The 5-year OS and DSS for all patients treated with CCRT were 51.3 and 64.3?%, respectively. The 5-year DSS with larynx preservation was 55.5?%. On multivariate analysis, the content of chemotherapy was a significant predictor of OS and DSS for patients undergoing CCRT; N stage was a significant prognostic factor for DSS and larynx preservation. Conclusion The treatment method including the indication for CCRT may be determined by the contents of the chemotherapy and the N stages of SCC of the hypopharynx.